Skip to main content
. Author manuscript; available in PMC: 2020 Aug 10.
Published in final edited form as: J Neurooncol. 2019 Mar 16;143(1):101–106. doi: 10.1007/s11060-019-03139-6

Table 1.

Patient characteristics and results of treatment

Age at diagnosis Gender Age at start of 131I-8H9 Number of Relapses Prior to 131I-8H9 Status when treated with 131I-8H9 CSF cGy/mCi Blood ROI Ventricle ROI Spine Months to Relapse after 131I-8H9 Status at last follow-up
3y Male 4y 7mo 0 Radio-graphic/cytologic remission 40.9 2.1 170 50.3 - NED
3y Female 3y 10mo 0 Radio-graphic/cytologic remission 22.5 3 147.8 81.7 - NED
1y Male 2y 8 mo 3 Minimal post-opresidual 179 2.3 392 57.6 1 DOD after local relapse

CSF, cerebrospinal fluid; 131-I-Omburtamab, iodinated 8H9 (Omburtamab); mo, months; OS, overall survival; ROI, region-of-interest; y, years; NED, no evaluable disease; DOD, died of disease.